Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    AP26113
Show Display Options
Rank Status Study
1 Unknown  A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
Conditions: Advanced Malignancies;   Carcinoma, Non-Small-Cell Lung;   Anaplastic Large Cell Lymphoma;   Diffuse Large Cell Lymphoma;   Inflammatory Myofibroblastic Tumors
Intervention: Drug: AP26113
2 Active, not recruiting A Phase 2, Multicenter, Randomized Study of AP26113
Conditions: Non-small Cell Lung Cancer;   Lung Cancer;   Advanced Malignancies;   Carcinoma
Intervention: Drug: AP26113
3 Recruiting ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients
Conditions: Non-small Cell Lung Cancer;   Lung Cancer;   Advanced Malignancies;   Carcinoma
Interventions: Drug: Brigatinib;   Drug: Xalkori (crizotinib)
4 Not yet recruiting Trial of Brigatinib After Treatment With Second-Generation ALK Inhibitors
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: brigatinib
5 Available An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Lung Cancer;   Advanced Malignancies;   Carcinoma
Intervention: Drug: Brigatinib

Study has passed its completion date and status has not been verified in more than two years.